South African CEO named Global Pharmaceutical CEO of the Year

Lynne du Toit, CEO of Eurolab, a South African oncology company, was named CPhI Excellence in Pharma: CEO of the Year for her clear vision of what the future of cancer treatment in Africa should look like of the South (SA).

Origin: supplied. Lynne du Toit, CEO of Eurolav

Selected from among the seven shortlisted CEOs of pharmaceutical companies from around the world, the judges of the jury of the World Pharmaceutical Ingredients Congress (CPhI) selected her for her bold and forward-looking leadership, her dynamism and her contribution to the whole Of the industry.

Speaking at the award ceremony in Milan, Italy last week, du Toit dedicated their award to their hardworking team at Eurolab in South Africa.

“This award is for scientists and developers who advance cancer treatment to improve outcomes for cancer patients, cancer patients in South Africa and globally, oncologists and healthcare workers who care for these patients and all the female CEOs who have had to balance family and work commitments to move forward, ”she said.

Having started his career in nursing and midwifery, du Toit entered the corporate world in the 1980s as a “rep”.

“At the time, pharmaceutical representatives were predominantly women and management teams were predominantly men. Women had to apply smartly and carefully juggle family and work demands to hold on and show their courage alongside their male executives, ”she said.

Reduce the cost of cancer drugs

Reducing the costs of cancer medicine, making treatment more accessible and affordable, and bringing solutions previously only available overseas in South Africa have underpinned his vision.

“The financial burden of cancer remains one of the biggest challenges for families suffering from this disease, and Eurolab is proud that today patients have to pay less than half of what they had to pay for. cancer medicine in 2010, ”says du Toit.

Founded in 2011 as a generic oncology drug company to make cancer treatment more affordable for South Africans, with Gabe Simaan, Chairman of the Eurolab Group, du Toit built Eurolab from scratch into a business of oncology which today, through its five divisions, offers an integrated and global solution against cancer to oncologists and their patients.

Today, it has a drug portfolio of over 30 products, and with the introduction of each new drug over the past decade, more patients have received cancer treatment at a more affordable price.

“In 2018, Eurolab lowered the price patients paid for chemotherapy by more than 50%, while the rest of the market saw an average increase of more than 30%,” said du Toit.

Du Toit says the Eurolab’s journey is far from over. “We are working tirelessly to expand access to innovative treatments, solutions and collaborations to strengthen the oncology response in South Africa to the growing incidence of cancer. ”

The CPhI Pharma Awards have been committed to recognizing excellence in the pharmaceutical industry since 2003.

Cathy W. Howerton